{"id":3004,"date":"2026-09-09T07:03:00","date_gmt":"2026-09-09T11:03:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3004"},"modified":"2026-09-09T19:39:34","modified_gmt":"2026-09-09T23:39:34","slug":"fda-accepts-mogenry-application-for-severe-retinitis-pigmentosa","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3004","title":{"rendered":"FDA Accepts MOGENRY Application for Severe Retinitis Pigmentosa"},"content":{"rendered":"

Evidence<\/strong> Company disclosure · Discovery<\/strong> September 9, 2026 · Importance<\/strong> 5\/5 · Direction<\/strong> Positive<\/p>\n

\"FDA<\/p>\n

Summary<\/h4>\n

FDA accepted and filed Nanoscope Therapeutics’ biologics license application for MOGENRY, or sonpiretigene isteparvovec, in retinitis pigmentosa with severe vision loss. The one-time intravitreal optogenetic therapy is intended to work across causal genotypes by making surviving inner-retinal cells light sensitive. Filing acceptance confirms administrative review readiness, not approval. The company did not disclose a review deadline, Priority Review status or an advisory-committee plan.<\/p>\n

What Happened<\/h4>\n

The application is supported by a Phase I\/IIa study, the randomized double-masked sham-controlled 27-patient RESTORE Phase IIb\/III trial and REMAIN long-term follow-up. Nanoscope says RESTORE met its primary and key secondary visual-acuity endpoints at Weeks 52 and 76 and reported no treatment-related serious adverse events. Previously presented three-year data showed approximately three ETDRS-line mean improvement in both dose groups, but the pivotal cohort remains small and the application’s integrated efficacy, sensitivity analyses and complete safety dataset are not public.<\/p>\n

Deep Analysis<\/h4>\n

Regulatory validation of a gene-agnostic vision-restoration thesis:<\/strong> Acceptance brings the first claimed genotype-independent optogenetic RP program into substantive FDA review and may validate a route for patients too genetically heterogeneous or advanced for photoreceptor-directed replacement. Randomization, masking and durability support the filing. Counterevidence includes the very small pivotal sample, limited external replication and uncertainty around how visual-acuity change translates to navigation, independence and daily function.<\/p>\n

A review with material evidentiary risk:<\/strong> FDA may still question multiplicity, dose pooling, durability, assay learning effects, missingness, manufacturing comparability or whether benefit is clinically meaningful across the intended severe-vision-loss population. AAV2 intravitreal delivery may simplify administration relative to subretinal surgery, but inflammation, neutralizing immunity and retreatment constraints require full review.<\/p>\n

Signal Extraction<\/h4>\n

Verified facts: BLA acceptance and filing; severe-vision-loss RP indication; one-time intravitreal AAV2 optogenetic therapy; randomized sham-controlled support. Missing facts: review goal date, review classification, advisory-committee plan, label breadth, integrated response rate, full ocular adverse-event profile, immunogenicity, vector shedding and commercial manufacturing inspection status. Upgrade evidence would be priority review, consistent FDA briefing materials and approval with a broad gene-agnostic label.<\/p>\n

Company and Product Background<\/h4>\n

Nanoscope Therapeutics is a private retinal-gene-therapy company. Retinitis pigmentosa comprises inherited retinal degenerations that progressively destroy photoreceptors, leaving many patients with severe vision loss and no genotype-specific treatment option.<\/p>\n

MOGENRY, formerly MCO-010, uses an AAV2 vector to express a multi-characteristic opsin in surviving retinal cells after office-based intravitreal injection. The design is genotype agnostic and seeks to bypass lost photoreceptors. It has received Fast Track and Orphan Drug designations for RP and Stargardt disease; those designations do not establish approval or benefit.<\/p>\n

InSilens Take<\/h4>\n

BLA acceptance is a major regulatory milestone for a modality that attempts to restore light sensitivity without correcting the underlying mutation. It is directionally constructive, but the pivotal evidence base is unusually small for a potentially broad gene-agnostic label. The central review question is whether durable visual-acuity gains are robust, clinically meaningful and supported by functional outcomes with an acceptable ocular and vector-safety profile.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n5 \/ 5 — the first reported FDA filing acceptance for a gene-agnostic optogenetic RP therapy<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nPositive — the application moved into review, while approval remains uncertain<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — filing status and supporting studies disclosed by the sponsor with trial identifiers<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nModerate — public data do not expose the complete regulatory dossier or FDA’s unresolved questions<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

FDA accepted and filed Nanoscope Therapeutics’ biologics license application for MOGENRY, or sonpiretigene isteparvovec, in retinitis pigmentosa with severe vision loss. The one-time intravitreal optogenetic therapy is intended to work across causal genotypes by…<\/p>\n","protected":false},"author":1,"featured_media":3017,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[644,643,646,645],"class_list":["post-3004","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-mogenry","tag-nanoscope-therapeutics","tag-optogenetics","tag-retinitis-pigmentosa"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3004"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3004\/revisions"}],"predecessor-version":[{"id":3024,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3004\/revisions\/3024"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3017"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}